Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F24%3AE0111070" target="_blank" >RIV/00843989:_____/24:E0111070 - isvavai.cz</a>

Výsledek na webu

<a href="https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38" target="_blank" >https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/bloodadvances.2024013212" target="_blank" >10.1182/bloodadvances.2024013212</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Popis výsledku v původním jazyce

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and its prevalence significantly increases in older patients. Furthermore, while the 5-year rate of overall survival (OS) for adults younger than 60 is around 40%, it decreases to 10% in patients above this age. The treatment landscape of AML is evolving from a curative/intensive vs palliative/low-intensity binary approach into new strategies that incorporate mutation-specific targeted therapies, apoptosis-inducing small molecules, and immunotherapy. Nonetheless, older patients who are unable to receive intensive chemotherapy with acceptable side effects and patients with relapsed/refractory disease continue to have dismal survival rates. Thus, the identification of new targets and treatment modalities is an unmet need.

Název v anglickém jazyce

Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Popis výsledku anglicky

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and its prevalence significantly increases in older patients. Furthermore, while the 5-year rate of overall survival (OS) for adults younger than 60 is around 40%, it decreases to 10% in patients above this age. The treatment landscape of AML is evolving from a curative/intensive vs palliative/low-intensity binary approach into new strategies that incorporate mutation-specific targeted therapies, apoptosis-inducing small molecules, and immunotherapy. Nonetheless, older patients who are unable to receive intensive chemotherapy with acceptable side effects and patients with relapsed/refractory disease continue to have dismal survival rates. Thus, the identification of new targets and treatment modalities is an unmet need.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood advances

ISSN

2473-9537

e-ISSN

2473-9537

Svazek periodika

8

Číslo periodika v rámci svazku

15

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

3875-3879

Kód UT WoS článku

001284281200001

EID výsledku v databázi Scopus

2-s2.0-85201467266